Endometrial tumor invasiveness is related to metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expressions

International Journal of Gynecological Cancer

Volumn 16, Issue 5, 2006, Pages 1911-1917

  Graesslin, O ^a,b,c   Cortez, A ^a,b   Uzan, C ^b   Birembaut, P ^c   Quereux, C ^c   Darai E ^a,b  

^a HÔPITAL TENON   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c REIMS UNIVERSITY HOSPITAL   (France)

Author keywords

Endometrial cancer; Immunohistochemistry; Metalloproteinase inhibitors; Metalloproteinases; Tumor progression

Indexed keywords

FORMALDEHYDE; GELATINASE A; GELATINASE B; MATRILYSIN; MONOCLONAL ANTIBODY; PARAFFIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ANTIBODY LABELING; ARTICLE; CANCER CLASSIFICATION; CANCER GROWTH; CANCER INVASION; CANCER RISK; CANCER TISSUE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; ENDOMETRIUM CARCINOMA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; LYMPH VESSEL; MYOMETRIUM; PARAMETERS OF MEASUREMENT AND ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; STAINING; STATISTICAL ANALYSIS;

CARCINOMA; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 7; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 33749152996     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2006.00717.x     Document Type: Article

References (47)

1. Birkedal-Hansen H, Moore WG, Bodden MK et al. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 1993;4:197-250.
2. Goffin F, Munaut C, Frankenne F et al. Expression pattern of metalloproteinases and tissue inhibitors of matrix-metalloproteinases in cycling human endometrium. Biol Reprod 2003;69:976-84.
3. Rodgers W. Matrix metalloproteinases and carcinogenesis. Hum Pathol 1999;30:363-4.
4. Tamakoshi K, Kikkawa F, Nawa A et al. Characterization of extracellular matrix degrading proteinase and its inhibitor in gynaecologic cancer tissues with clinically different metastatic form. Cancer 1995;76:2565-71.
5. Wojtowicz-Praga SM, Dickson RB, Hawkins MJ. Matrix metalloproteinase inhibitors. Invest New Drugs 1997;15:61-75.
6. Raza SL, Cornelius LA. Matrix metalloproteinases: pro- and antiangiogenic activities. J Investig Dermatol Symp Proc 2000;5:47-54.
7. Van den Steen PE, Opdenakker G, Wormald MR, Dwek RA, Rudd PM. Matrix remodelling enzymes, the protease cascade and glycosylation. Biochimica et Biophysica Acta 2001;1528:61-73.
8. Woessner JF. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 1991;5:2145-54.
9. Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997;89:1260-70.
10. Ray JM, Stetler-Stevenson WG. The role of matrix metalloproteases and their inhibitors in tumour invasion, metastasis and angiogenesis. Eur Respir J 1994;7:2062-72.
11. Jones JL, Glynn P, Walker RA. Expression of MMP-2 and MMP-9, their inhibitors and the activator MT1-MMP in primary breast carcinomas. J Pathol 1999;189:161-8.
12. Maeta H, Ohgi S, Terada T. Protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinase 1 and 2 in papillary thyroid carcinomas. Virchows Arch 2001;438:121-8.
13. Sakata K, Shigemasa K, Nagai N, Ohama K. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1 and TIMP-2) in common epithelial tumors of the ovary. Int J Oncol 2000;17:673-81.
14. Prat J. Prognostic parameters of endometrial carcinoma. Hum Pathol 2004;35:649-62.
15. Soini Y, Alarakkola E, Auto-Harmainen H. Expression of messenger RNAs for metalloproteinases 2 and 9, type IV collagen, and laminin in nonneoplastic and neoplastic endometrium. Hum Pathol 1997;28:220-6.
16. Di Nezza LA, Misajon A, Zhang J et al. Presence of active gelatinases in endometrial carcinoma and correlation of matrix metalloproteinase expression with increasing tumor grade and invasion. Cancer 2002;94:1466-75.
17. Iurlaro M, Loverro G, Vacca A et al. Angiogenesis extent and expression of matrix metalloproteinase -2 and -9 correlate with upgrading and myometrial invasion in endometrial carcinoma. Eur J Clin Invest 1999;29:793-801.
18. Aglund A, Rauvala M, Puistola U et al. Gelatinases A and B (MMP-2 and MMP-9) in endometrial cancer-MMP-9 correlates to the grade and the stage. Gynecol Oncol 2004;94:699-704.
19. Ueno H, Yamashita K, Azumano I, Inoue M, Okada Y. Enhanced production and activation of matrix metalloproteinase-7 (matrilysin) in human endometrial carcinomas. Int J Cancer 1999;84:470-7.
20. Laird SM, Dalton CF, Okon MA, Bunning RAD, Marshall R, Li TC. Metalloproteinases and tissue inhibitor of metalloproteinase 1 (TIMP-1) in endometrial flushings from pre- and post-menopausal women and from women with endometrial carcinoma. J Reprod Fertil 1999;115:225-32.
21. Määtä M, Soini Y, Liakka A, Autio-Harmainen H. Localization of MT1-MMP, TIMP-1, TIMP-2 and TIMP-3 messenger RNA in normal, hyperplastic and neoplastic endometrium. Enhanced expression by endometrial carcinomas is associated with low differentiation. Am J Clin Pathol 2000;114:402-11.
22. Moser PL, Hefler L, Tempfer C, Neunteufel W, Kieback DG, Gitsch G. Immunohistochemical detection of matrix metalloproteinases (MMP) 1 and 2, and tissue inhibitor of metalloproteinase 2 (TIMP 2) in stage I and II endometrial cancer. Anticancer Res 1999;19:2365-8.
23. Benedet JL, Bender H, Jones H III, Ngan HY, Pecorrelli S. FIGO staging classifications and clinical practice guidelines in the management of gynaecologic cancers. FIGO committee on Gynecologic Oncology. Int J Gynaecol Obstet 2000;70:209-62.
24. Nomura H, Sato H, Seiki M, Mai M, Okada Y. Expression of membrane - type matrix metalloproteinase in human gastric carcinomas. Cancer Res 1995;55:3263-6.
25. Tokuraku M, Sato H, Murakami S, Okada Y, Watanabe Y, Seiki M. Activation of the precursor of gelatinase A/72 kDa type IV collagenase/MMP-2 in lung carcinomas correlates with the expression of membrane-type matrix metalloproteinase (MT-MMP) and with lymph node metastasis. Int J Cancer 1995;64:355-9.
26. Davies B, Miles DW, Happerfield LC et al. Activity of type IV collagenases in benign and malignant breast disease. Br J Cancer 1993;67:1126-31.
27. Guo W, Chen G, Zhu C, Wang H. Expression of matrix metalloproteinase-2, -9 and it's tissue inhibitor-1, -2 in endometrial carcinoma. Zhonghua Fu Chan Ke Za Zhi 2002;37:604-7.
28. Fan YZ, Zhang JT, Yang HC, Yang YQ. Expression of MMP-2, TIMP-2 protein and the ratio of MMP-2/TIMP-2 in gallbladder carcinoma and their significance. World J Gastroenterol 2002;8:1138-43.
29. Giannelli G, Bergamini C, Marinosci F et al. Clinical role of MMP-2/TIMP-2 imbalance in hepatocellular carcinoma. Int J Cancer 2002;97:425-31.
30. Xiao M, Zhou NX, Huang ZQ et al. The ratio of MMP-2 to TIMP-2 in hilar cholangiocarcinoma: a semi-quantitative study. Hepatobiliary Pancreat Dis Int 2004;3:599-602.
31. Uzan C, Cortez A, Dufournet C, Fauvet R, Siffroi JP, Daraï E. Eutopic endometrium and peritoneal, ovarian and bowel endometriotic tissues express a different profile of matrix metalloproteinases -2, -3, and -11, and of tissue inhibitor metalloproteinases -1 and -2. Virchows Arch 2004;445:603-9.
32. Ferguson SE, Olshen AB, Viale A, Awtrey CS, Barakat RR, Boyd J. Gene expression profiling of tamoxifen-associated uterine cancers: evidence for two molecular classes of endometrial carcinoma. Gynecol Oncol 2004;92:719-25.
33. Polette M, Nawrocki-Raby B, Gilles C, Clavel C, Birembaut P. Tumour invasion and matrix metalloproteinases. Crit Rev Oncol Hematol 2004;49:179-86.
34. Heppner KJ, Matrisian LM, Jensen RA, Rodgers WH. Expression of most matrix metalloproteinase members in breast cancer represents a tumor-induced host response. Am J Pathol 1996;149:273-82.
35. Muller D, Breathnach R, Engelmann A et al. Expression of collagenase-related metalloproteinase genes in human lung or head and neck tumors. Int J Cancer 1991;48:550-6.
36. Wang FQ, So J, Reierstad S, Fishman DA. Matrilysin (MMP-7) promotes invasion of ovarian cancer cells by activation of progelatinase. Int J Cancer 2005;114:19-31.
37. Wilson CL, Heppner KJ, Labosky PA, Hogan BLM, Matrisian LM. Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc Natl Acad Sci U S A 1997;94:1402-7.
38. Lopata A, Agresta F, Quinn MA, Smith C, Ostor AG, Salamonsen LA. Detection of endometrial cancer by determination of matrix metalloproteinases in the uterine cavity. Gynecol Oncol 2003;90:318-24.
39. Goffin F, Frankenne F, Beliard A et al. Human endometrial epithelial cells modulate the activation of gelatinase a by stromal cells. Gynecol Obstet Invest 2002;53:105-11.
40. Kokorine I, Marbaix E, Henriet P et al. Focal cellular origin and regulation of interstitial collagenase (matrix metalloproteinase-1) are related to menstrual breakdown in the human endometrium. J Cell Sci 1996;109(Pt 8):2151-60.
41. Salamonsen LA, Zhang J, Hampton A, Lathbury L. Regulation of matrix metalloproteinases in human endometrium. Hum Reprod 2000;15(Suppl. 3):112-9.
42. Zhang J, Hamton AL, Nie G, Salamonsen LA. Progesterone inhibits activation of latent matrix metalloproteinase (MMP)-2 by membrane-type 1 MMP: enzymes co-ordinately expressed in human endometrium. Biol Reprod 2000;62:85-94.
43. Liokumovich P, Goldberg I, Davidson B, Gotlieb WH, Zahavi T, Ben Baruch G. Expression of metalloproteinases endometrial stromal sarcoma: immunohistochemical study using image analysis. J Clin Pathol 1999;52(Pt 3):198-202.
44. Leong AS-Y. Quantitation in immunohistology: fact or fiction? Appl Immunohistochem Mol Morphol 2004;12:1-7.
45. Wiegand S, Dünne AA, Müller HH et al. Metaanalysis of the significance of matrix metalloproteinases for lymph node disease in patients with head and neck squamous cell carcinoma. Cancer 2005;104:94-100.
46. Budwit-Novotny A, McCarty KS, Cox EB et al. Immunohistochemical analyses of estrogen receptor in endometrial adenocarcinoma using a monoclonal antibody. Cancer Res 1986;46:5419-25.
47. Lessey BA, Castelbaum AJ, Wolf L et al. Use of integrins to date the endometrium. Fertil Steril 2000;73:779-87.